Date: 2015-05-13
Type of information: Grant
Company: Cell Cure Neurosciences (Israel)
Investors: Office of the Chief Scientist (OCS -Israel)
Amount: 6.24 million shekels (approximately $1.61 million )
Funding type: grant
Planned used: The grant will help finance the development of OpRegen®, a cell-based therapeutic product that consists of animal product-free retinal pigment epithelial (RPE) cells with high purity and potency. Cell Cure is now enrolling patients at Hadassah University Medical Center in Jerusalem, Israel , in a clinical Phase I/IIa dose-escalation study evaluating the safety and efficacy of OpRegen® for geographic atrophy, the severe stage of the dry form of age-related macular degeneration (dry-AMD). The Phase I/IIa clinical trial was opened in February 2015 following regulatory clearance from the FDA and the Israeli Ministry of Health. The trial consists of four cohorts and will evaluate three different dose regimens.
Others: * On May 13, 2015, BioTime and its subsidiary Cell Cure Neurosciences announced that Cell Cure has been awarded a grant for 2015 of 6.24 million shekels (approximately $1.61 million ) from Israel\'s Office of the Chief Scientist (OCS) to help finance the development of OpRegen®, a cell-based therapeutic product that consists of animal product-free retinal pigment epithelial (RPE) cells with high purity and potency.
Therapeutic area:
